Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

Effect of Single Hemoperfusion Combined with Hemodialysis on Macromolecular Uremic Toxin

Acute Effect of One Session of Hemodiafiltration with Endogenous Reinfusion on Uremic Toxins and Inflammatory Mediators.

Progress of Middle Molecular Weight Uremic Toxins and Removal Techniques

The short-term clinical effects of super-high flux hemodialysis on refractory complications in maintenance hemodialysis patients

Investigation on the Effect of Hemodialysis Combined with MDT Multimode Intervention on Renal Fibrosis Degree and Renal Function Improvement in Uremia Patients

Effectiveness of Combined Hemodialysis-Hemadsorption Therapy in Improving Uremic Toxin Clearance, Inflammatory Markers, and Symptoms in Maintenance Hemodialysis Patients

Impact of hemoperfusion combined with hemodialysis on left ventricular function in patients with maintenance hemodialysis

Effects of High Flux Hemodialysis on TLC, Immunoglobulin Level and QOL in TreatmentChronic Renal Failure Uremia

Upgrade of dialysate quality improves the microinflammation in maintenance haemodialysis patients

The Influence of Different Blood Purification Methods on Anemia of Uremic Patients

High-flux Hemodialysis Efficiently Removes Β_2-Microglobin and Improves Inflammation Status in Maintain Hemodialysis Patients

Hemodiafiltration with endogenous reinfusion for uremic toxin removal in patients undergoing maintenance hemodialysis: a pilot study

Randomized Control Study on Hemoperfusion Combined with Hemodialysis Versus Standard Hemodialysis: Effects on Middle-Molecular-Weight Toxins and Uremic Pruritus

Primary Clinical Experience in High Risk Uremic Patients Converted from Conventional to Short Daily Hemodialysis

Relationship Between Ultrafiltration Rate and Cardiovascular Death in Maintenance Hemodialysis Patients

Effect of parathyroid hormone on myocardial damage,cardiac structure and function in maintenance hemodialysis patients

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial

Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites

The solutes removal capability in four different membrane dialyzers in hemodialysis maintenance patients

Improved Dialysis Removal of Protein-Bound Uraemic Toxins with a Combined Displacement and Adsorption Technique